Citizens lowers Skye Bioscience stock price target to $4 from $16, maintains Market Outperform rating
NegativeFinancial Markets

Citizens has significantly reduced its stock price target for Skye Bioscience from $16 to $4, while still maintaining a Market Outperform rating. This drastic cut reflects concerns about the company's future performance and market conditions, which could impact investor confidence and stock value. Understanding these changes is crucial for investors looking to navigate the volatile biotech sector.
— Curated by the World Pulse Now AI Editorial System